Overview

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection

Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of ABT-493/ABT-530 in adults with genotype 2 chronic hepatitis C virus (HCV) infection.
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie